SCHEMBL9963178

SCHEMBL9963178

CC(C)c1nc(-c2cccnc2)no1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.66
NPSR1 Q6W5P4 2/20 0.66
CHRNB2 P17787 1/20 0.65
CHRNA5 P30532 1/20 0.65
CHRNA4 P43681 1/20 0.65
SMN1; SMN2 Q16637 4/20 0.59
TP53 P04637 3/20 0.59
NFKB1 P19838 1/20 0.59
NFKB2 Q00653 1/20 0.59
RELA Q04206 1/20 0.59
NPC1 O15118 5/20 0.58
RAB9A P51151 5/20 0.58
MAPT P10636 3/20 0.58
KDM4E B2RXH2 2/20 0.58
HPGD P15428 2/20 0.58
HSD17B10 Q99714 1/20 0.58
TSHR P16473 4/20 0.56
AHR P35869 1/20 0.56
POLB P06746 1/20 0.55
PPARA Q07869 7/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4313971 0.87 ALDH1A1 (0.62) ALDH1A1NPSR1CHRNB2CHRNA5CHRNA4
SCHEMBL16373615 0.84 ALDH1A1 (0.59) ALDH1A1NPSR1CHRNB2CHRNA5CHRNA4
SCHEMBL1436206 0.84 ALDH1A1 (0.59) ALDH1A1NPSR1CHRNB2CHRNA5CHRNA4
SCHEMBL18997586 0.84 ALDH1A1 (0.59) ALDH1A1NPSR1CHRNB2CHRNA5CHRNA4
SCHEMBL17788457 0.83 ALDH1A1 (0.58) ALDH1A1NPSR1CHRNB2CHRNA5CHRNA4
SCHEMBL6978731 0.82 HTT (0.62) ALDH1A1NPSR1SMN1; SMN2TP53NFKB1
SCHEMBL2657248 0.79 CHRNB2 (0.69) ALDH1A1NPSR1CHRNB2CHRNA5CHRNA4
SCHEMBL1422890 0.79 CHRNB2 (1.00) ALDH1A1NPSR1CHRNB2CHRNA5CHRNA4
SCHEMBL11020935 0.79 SMN1; SMN2 (0.59) ALDH1A1NPSR1SMN1; SMN2TP53NFKB1
SCHEMBL12611843 0.78 CHRNB2 (0.58) ALDH1A1NPSR1CHRNB2CHRNA5CHRNA4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230286997-A1 Compounds for the Treatment of Cancer and Inflammatory Disease SHY Therapeutics LLC 2023-09-14 US disclosed
US-11560390-B2 Compounds for the treatment of cancer and inflammatory disease SHY Therapeutics LLC (US) 2023-01-24 US disclosed
US-20170174699-A1 COMPOUNDS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASE SHY Therapeutics LLC 2017-06-22 US disclosed
US-8354403-B2 Pyrrolidine derived beta 3 adrenergic receptor agonists MERCK SHARP & DOHME CORP. (US) 2013-01-15 US disclosed
US-20120157432-A1 NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS MERCK SHARP & DOHME, CORP. (US) 2012-06-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11560390-B2 Compounds for the treatment of cancer and inflammatory disease MAPK6, MAP3K6, MAPK4 ALDH1A1 2765/4885NPSR1 3909/4885CHRNB2 4681/4885
US-20230286997-A1 Compounds for the Treatment of Cancer and Inflammatory Disease MAPK6, MAP3K6, MAPK4 ALDH1A1 2765/4885NPSR1 3909/4885CHRNB2 4681/4885
US-20120157432-A1 NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS ADRB3, ADRB1, ADRB2 ALDH1A1 534/4885NPSR1 93/4885CHRNB2 43/4885
US-20170174699-A1 COMPOUNDS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASE MAPK6, MAP3K6, MAPK4 ALDH1A1 2765/4885NPSR1 3909/4885CHRNB2 4681/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.